DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for drug allergy — screening already-approved drugs against its 34-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDrug allergy maps to a 34-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for drug allergy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein tyrosine phosphatase receptor type D (PTPRD) — PTPRD is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet flcdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2YD6 · 1.35 Å · ligand CITRATE ANION (FLC). Experimental structure, not a prediction.
What the evidence adds up to
A 2012 review of diagnostic issues in paediatric drug allergy states that the drug provocation test remains the gold standard, particularly for children with a benign rash while taking antibiotics. The review notes that systematic approaches, if implemented, will likely reduce the number of children inappropriately labelled as drug allergic. Several new diagnostic tools are under investigation and provide promising results, but the authors also state that general lack of knowledge of the pathomechanisms greatly hampers the ability to correctly diagnose allergic drug reactions.
A 2018 overview describes drug allergic reactions as adverse reactions mediated by immunological mechanisms, usually not related to the pharmacological actions of the drug. The review was conducted as a nonsystematic review and attempts to describe the complexity of drug allergy. It states that despite all advances, drug allergy is not yet fully established and understood. An exceptional contribution was brought by pharmacogenomics, even though a specific pharmacogenetic association has only been defined for a very limited number of drugs. The authors call for further studies to obtain clearer answers when managing each individual case.
A 2023 review article on drug allergy states there is no published literature on the incidence in India. It notes that drug allergy can lead to substantial mortality and morbidity. The review describes that drugs elicit immune responses in several ways and can produce immunological reactions varying from Type I to Type 4 hypersensitivity. It states that a systematic approach to a suspected drug allergy can help in better management, but provides no new trial data, no specific drug repurposing evidence, and no quantitative outcomes such as survival or response rates.
Across these reviews, no drug is mentioned as repurposed for drug allergy. No clinical trial results, no response rates, and no survival data are reported. What is missing is any prospective trial testing a specific intervention, any validated biomarker for diagnosis or prediction, any pharmacogenetic test that has been implemented in routine care, and any funding for the large, stratified studies needed to move beyond descriptive reviews.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Allergy and Clinical Immunology · 2012 · 18 citations
Diagnostic issues in pediatric drug allergy
AbstractPURPOSE OF REVIEW: The serious health hazards posed by drug allergies have long been recognized and are commonly encountered in daily pediatric practice. Our general lack of knowledge of the pathomechanims greatly hampers our ability to correctly diagnose allergic drug reactions. The present review addresses the most recent literature regarding the diagnosis of allergy for the most commonly implicated drugs in children, that is, antibiotics, nonsteroidal anti-inflammatory drugs (NSAID) and vaccines. RECENT FINDINGS: Systematic approaches have been proposed and, if implemented, will likely reduce the number of children being inappropriately labeled as 'drug allergic'. In case of suspicion of an allergy, a complete allergy work-up should always be performed. This evaluation based on carefully selected diagnostic tests will differ according to the drug involved and the mechanisms suspected. The drug provocation test remains the gold standard and has gained in importance, particularly in children presenting with a benign rash while taking antibiotic treatment. Several new diagnostic tools are currently under investigation and provide promising results. SUMMARY: Accurate diagnosis of drug allergy is important not only to prevent serious or even life-threatening reactions, but also to avoid unnecessary drug restriction associated with increased resistance and healthcare costs.
Overview of Drug Allergy: From Immunogenetic Basis to Practice
AbstractDrug therapy is often a balance between the beneficial and harmful effects of drugs. Drug allergic reactions are adverse reactions mediated by immunological mechanisms and usually not related to the pharmacological actions of the drug. They can be classified based either on the clinical presentation or the underlying immunological mechanism. Although uncommon, drug allergic reactions are unpredictable and can be very severe, even life threatening. The aim of this review was to provide clinicians from different medical specialties with a working tool to improve management of their patients with suspected drug allergy. It was conducted as a nonsystematic review, and attempts to describe the complexity of drug allergy. The information included ranges from pathophysiology to the heterogeneous clinical presentation, with a special focus on the drugs most frequently involved, as well as a classification of reactions and risk factors. Despite all advances in this challenging and complex field of allergy and clinical immunology, drug allergy is not yet fully established and understood. An exceptional contribution was brought by pharmacogenomics, even though a specific pharmacogenetic association has only been defined for a very limited number of drugs. Further studies are needed to obtain clearer answers when managing each individual case of drug allergy.
AbstractDrug allergy is an immunologically mediated adverse reaction that can lead to substantial mortality and morbidity. However, there is no published literature on the incidence in India. Knowledge and management of drug allergies are imperative in day-to-day practice. Drugs elicit immune responses in several ways and are also capable of producing immunological reactions that may vary from Type I to Type 4 hypersensitivity reactions. There are risk factors that make certain people more vulnerable to such reactions. A systematic approach to a suspected drug allergy can help in better management of the same.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
